SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Indoco Remedies’ Clinical Research Organization

22 Jul 2022 Evaluate

The United States Food and Drug Administration (USFDA) has successful concluded inspection at Indoco Remedies’ Clinical Research Organization – AnaCipher. The inspection conducted between July 11th- 15th, 2022. During the remote record review, the agency did not identify any objectionable conditions and thus, did not have any observations. This inspection was conducted by the Division of New Drug Study Integrity, Office of Study Integrity and Surveillance of USFDA. The scope of the inspection included Bioanalytical phase of multiple studies, of which one was ‘First to File’.

Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs) in India.

Indoco Remedies Share Price

228.20 -23.05 (-9.17%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×